bluebird bio, Inc.
(NASDAQ : BLUE)

( )
BLUE After-Hours: () as of PM
Volume Open Day's Low Day's High 52 Wk Low 52 Wk High Bid Ask EPS PE Ratio Shares Market Cap Dividend Ex-Div Date Yield
Daily Pre-Market Movers
Receive our daily pre-market mover email, free.
100% secure: your email is never shared, and you may opt out at any time.
...
Health Technology » Biotechnology
symbolcompany%chnglast%shortavg$volume
AMGNAmgen Inc.
0.66%196.941.3%$565.97m
GILDGilead Sciences, Inc.
0.70%66.420.9%$368.71m
BIIBBiogen Inc.
1.35%238.791.3%$340.32m
ILMNIllumina, Inc.
1.43%309.573.5%$338.07m
ALXNAlexion Pharmaceuticals, Inc.
0.62%106.322.0%$332.28m
CELGCelgene Corporation
0.42%99.371.3%$309.99m
REGNRegeneron Pharmaceuticals, Inc.
3.40%295.872.6%$188.33m
VRTXVertex Pharmaceuticals Incorporated
1.12%178.121.9%$186.01m
AAgilent Technologies, Inc.
-0.18%77.931.6%$185.14m
EXASExact Sciences Corporation
0.55%103.9724.1%$152.91m
SRPTSarepta Therapeutics, Inc.
-3.34%82.5114.6%$139.60m
ACADACADIA Pharmaceuticals Inc.
-2.26%40.7413.9%$129.03m
INCYIncyte Corporation
3.96%81.212.5%$93.98m
ALDRAlder Biopharmaceuticals, Inc.
-0.11%18.6410.2%$81.98m
BMRNBioMarin Pharmaceutical Inc.
-1.38%74.954.3%$76.08m

Company Profile

bluebird bio, Inc. is a clinical-stage biotechnology company, which engages in the development of potential gene therapies for severe genetic diseases and cancer. Its integrated product platform includes gene therapy, cancer immunotherapy, and gene editing. Its product pipeline includes Lenti-D, LentiGlobin, BCL11a shRNA, bb2121, and bb21217. The company was founded by Philippe Leboulch and Ronald C. Dorazio on April 16, 1992 and is headquartered in Cambridge, MA.